1.74
price up icon3.57%   0.06
pre-market  Pre-market:  1.74  
loading
Acrivon Therapeutics Inc stock is traded at $1.74, with a volume of 288.66K. It is up +3.57% in the last 24 hours and down -67.23% over the past month. Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes the Phase 2 lead program, ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1, a closely related protein serine/threonine kinase.
See More
Previous Close:
$1.68
Open:
$1.69
24h Volume:
288.66K
Relative Volume:
2.82
Market Cap:
$54.55M
Revenue:
-
Net Income/Loss:
$-69.00M
P/E Ratio:
-0.6259
EPS:
-2.78
Net Cash Flow:
$-55.26M
1W Performance:
-33.33%
1M Performance:
-67.23%
6M Performance:
-75.53%
1Y Performance:
-73.99%
1-Day Range:
Value
$1.62
$1.8998
1-Week Range:
Value
$1.56
$2.97
52-Week Range:
Value
$1.56
$11.90

Acrivon Therapeutics Inc Stock (ACRV) Company Profile

Name
Name
Acrivon Therapeutics Inc
Name
Phone
617-207-8979
Name
Address
480 ARSENAL WAY, SUITE 100, WATERTOWN
Name
Employee
78
Name
Twitter
Name
Next Earnings Date
2025-03-26
Name
Latest SEC Filings
Name
ACRV's Discussions on Twitter

Compare ACRV with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
ACRV
Acrivon Therapeutics Inc
1.74 54.55M 0 -69.00M -55.26M -2.78
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
483.49 124.48B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
625.60 67.45B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
583.62 35.60B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
266.83 34.53B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
274.78 29.15B 3.81B -644.79M -669.77M -6.24

Acrivon Therapeutics Inc Stock (ACRV) Upgrades & Downgrades

Date Action Analyst Rating Change
Jan-31-25 Initiated KeyBanc Capital Markets Overweight
Sep-16-24 Upgrade Ladenburg Thalmann Neutral → Buy
Apr-29-24 Downgrade Ladenburg Thalmann Buy → Neutral
Mar-01-24 Initiated JMP Securities Mkt Outperform
Dec-15-23 Resumed Jefferies Buy
Oct-05-23 Initiated Maxim Group Buy
Jun-02-23 Initiated Oppenheimer Outperform
May-08-23 Initiated BMO Capital Markets Outperform
Apr-27-23 Initiated Ladenburg Thalmann Buy
Apr-20-23 Initiated H.C. Wainwright Buy
Dec-12-22 Initiated Cowen Outperform
Dec-12-22 Initiated Jefferies Buy
Dec-12-22 Initiated Piper Sandler Overweight
View All

Acrivon Therapeutics Inc Stock (ACRV) Latest News

pulisher
Mar 29, 2025

Q1 Earnings Forecast for ACRV Issued By HC Wainwright - Defense World

Mar 29, 2025
pulisher
Mar 29, 2025

Acrivon Therapeutics (NASDAQ:ACRV) and Astellas Pharma (OTCMKTS:ALPMY) Head to Head Contrast - Defense World

Mar 29, 2025
pulisher
Mar 28, 2025

H.C. Wainwright maintains Acrivon stock Buy rating, $19 target By Investing.com - Investing.com Australia

Mar 28, 2025
pulisher
Mar 28, 2025

Acrivon Therapeutics, Inc. (ACRV) Upgraded to Buy: Here's What You Should Know - MSN

Mar 28, 2025
pulisher
Mar 28, 2025

Acrivon Therapeutics price target lowered to $10 from $18 at Oppenheimer - TipRanks

Mar 28, 2025
pulisher
Mar 28, 2025

Here's Why Acrivon Therapeutics, Inc. (ACRV) is Poised for a Turnaround After Losing -52.81% in 4 Weeks - Yahoo Finance

Mar 28, 2025
pulisher
Mar 28, 2025

H.C. Wainwright maintains Acrivon stock Buy rating, $19 target - Investing.com India

Mar 28, 2025
pulisher
Mar 28, 2025

HC Wainwright Has Lowered Expectations for Acrivon Therapeutics (NASDAQ:ACRV) Stock Price - Defense World

Mar 28, 2025
pulisher
Mar 28, 2025

FY2029 Earnings Estimate for ACRV Issued By HC Wainwright - Defense World

Mar 28, 2025
pulisher
Mar 28, 2025

Cantor Fitzgerald Reaffirms “Overweight” Rating for Acrivon Therapeutics (NASDAQ:ACRV) - Defense World

Mar 28, 2025
pulisher
Mar 27, 2025

Acrivon Therapeutics reports Q4 EPS (60c), consensus (70c) - TipRanks

Mar 27, 2025
pulisher
Mar 27, 2025

Acrivon Therapeutics Provides Program Updates and Fourth Quarter and Full Year 2024 Financial Results - GlobeNewswire

Mar 27, 2025
pulisher
Mar 27, 2025

Breakthrough: Acrivon's Cancer Drug Shows 35% Response Rate in Hard-to-Treat Endometrial Cancer - Stock Titan

Mar 27, 2025
pulisher
Mar 27, 2025

Acrivon Therapeutics Reports 2024 Financial Results and Progress - TipRanks

Mar 27, 2025
pulisher
Mar 27, 2025

Long Term Trading Analysis for (ACRV) - news.stocktradersdaily.com

Mar 27, 2025
pulisher
Mar 27, 2025

Acrivon narrows focus for ACR-368 in endometrial cancer - BioWorld MedTech

Mar 27, 2025
pulisher
Mar 27, 2025

JMP maintains Acrivon stock with $17 target following update By Investing.com - Investing.com Australia

Mar 27, 2025
pulisher
Mar 26, 2025

Acrivon Therapeutics stock target cut to $19 by H.C. Wainwright - Investing.com South Africa

Mar 26, 2025
pulisher
Mar 26, 2025

12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga

Mar 26, 2025
pulisher
Mar 26, 2025

Crude Oil Gains Over 1%; Cintas Shares Jump After Q3 Earnings - Benzinga

Mar 26, 2025
pulisher
Mar 26, 2025

Nasdaq Down 1%; Dollar Tree To Sell Family Dollar Business For $1 Billion - Benzinga

Mar 26, 2025
pulisher
Mar 26, 2025

Humacyte to raise $50M; Acrivon to focus on prexasertib in endometrial cancer - Endpoints News

Mar 26, 2025
pulisher
Mar 26, 2025

Cantor Fitzgerald maintains Overweight on Acrivon stock By Investing.com - Investing.com South Africa

Mar 26, 2025
pulisher
Mar 26, 2025

Cantor Fitzgerald maintains Overweight on Acrivon stock - Investing.com

Mar 26, 2025
pulisher
Mar 26, 2025

JMP maintains Acrivon stock with $17 target following update - Investing.com India

Mar 26, 2025
pulisher
Mar 25, 2025

Acrivon Therapeutics’ SWOT analysis: innovative oncology firm’s stock potential By Investing.com - Investing.com Australia

Mar 25, 2025
pulisher
Mar 25, 2025

Citizens JMP reiterates Acrivon stock with $17 target By Investing.com - Investing.com South Africa

Mar 25, 2025
pulisher
Mar 24, 2025

Acrivon Therapeutics’ SWOT analysis: innovative oncology firm’s stock potential - Investing.com

Mar 24, 2025
pulisher
Mar 24, 2025

Citizens JMP reiterates Acrivon stock with $17 target - Investing.com

Mar 24, 2025
pulisher
Mar 24, 2025

Acrivon Therapeutics: Promising Oncology Advancements and Strategic Positioning Justify Buy Rating - TipRanks

Mar 24, 2025
pulisher
Mar 20, 2025

Acrivon Therapeutics (ACRV) to Release Quarterly Earnings on Thursday - Defense World

Mar 20, 2025
pulisher
Mar 19, 2025

Acrivon Therapeutics to Host Corporate R&D Event to Provide - GlobeNewswire

Mar 19, 2025
pulisher
Mar 19, 2025

Acrivon Unveils Next-Gen Cancer Platform: Key Updates from Leading Oncology Experts - StockTitan

Mar 19, 2025
pulisher
Mar 19, 2025

Acrivon Therapeutics to Host Virtual R&D Event on March 25, 2025, Featuring Updates on ACR-368 and ACR-2316 - Nasdaq

Mar 19, 2025
pulisher
Mar 17, 2025

Acrivon Therapeutics Names Adam Levy as CFO -March 17, 2025 at 05:36 am EDT - Marketscreener.com

Mar 17, 2025
pulisher
Mar 17, 2025

(ACRV) Investment Report - Stock Traders Daily

Mar 17, 2025
pulisher
Mar 16, 2025

Acrivon Therapeutics, Inc. (NASDAQ:ACRV) Short Interest Down 33.7% in February - The AM Reporter

Mar 16, 2025
pulisher
Mar 15, 2025

Acrivon Therapeutics appoints new CFO as predecessor steps down By Investing.com - Investing.com Australia

Mar 15, 2025
pulisher
Mar 15, 2025

Short Interest in Acrivon Therapeutics, Inc. (NASDAQ:ACRV) Decreases By 33.7% - Defense World

Mar 15, 2025
pulisher
Mar 14, 2025

Acrivon Therapeutics appoints new CFO as predecessor steps down - Investing.com

Mar 14, 2025
pulisher
Mar 14, 2025

Acrivon Therapeutics Appoints New Chief Financial Officer - TipRanks

Mar 14, 2025
pulisher
Mar 14, 2025

Analysts Set Acrivon Therapeutics, Inc. (NASDAQ:ACRV) Price Target at $23.67 - Defense World

Mar 14, 2025
pulisher
Mar 12, 2025

Acrivon Therapeutics Stock Is Soaring Tuesday: What's Going On? - MSN

Mar 12, 2025
pulisher
Feb 24, 2025

When (ACRV) Moves Investors should Listen - Stock Traders Daily

Feb 24, 2025
pulisher
Feb 18, 2025

Acrivon Therapeutics, Inc. (NASDAQ:ACRV) Short Interest Update - Defense World

Feb 18, 2025
pulisher
Feb 17, 2025

Acrivon Therapeutics, Inc. (NASDAQ:ACRV) Receives $23.67 Average Target Price from Analysts - Defense World

Feb 17, 2025

Acrivon Therapeutics Inc Stock (ACRV) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$73.44
price up icon 2.00%
$68.32
price up icon 0.56%
$31.28
price up icon 0.35%
$20.46
price up icon 8.83%
$93.32
price up icon 3.36%
biotechnology ONC
$274.78
price up icon 1.38%
Cap:     |  Volume (24h):